Jan 2, 2022 · These findings support the clinical benefit of D-Rd in transplant-ineligible NDMM patients enrolled in MAIA, regardless of frailty status.
These findings support the clinical benefit of D-Rd in transplant-ineligible NDMM patients enrolled in MAIA, regardless of frailty status.
In the phase 3 MAIA study of patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab plus lenalidomide/dexamethasone (D-Rd) ...
May 9, 2023 · Conclusions: Frail TIE patients with NDMM treated with D-Rd reported improvements in GHS (an overall HRQoL measure) and physical functioning, ...
Missing: plus | Show results with:plus
People also ask
Can you take daratumumab in combination with lenalidomide and dexamethasone?
What are the side effects of daratumumab lenalidomide dexamethasone?
What is the life expectancy of someone on daratumumab?
How long can you stay on daratumumab?
Dec 12, 2022 · Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-ineligible Newly Diagnosed Multiple Myeloma: MAIA Age Subgroup ...
In this trial, patients with newly diagnosed multiple myeloma who were transplant-ineligible were randomized to receive daratumumab (Darzalex), lenalidomide ( ...
In the phase 3 MAIA study of patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab plus lenalidomide/dexamethasone (D-Rd) ...
Apr 1, 2022 · In the phase 3 MAIA study of patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab plus lenalidomide/ ...
May 29, 2019 · Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell ...
Jan 2, 2022 · We present a subgroup analysis of MAIA by frailty status. Frailty assessment was performed retrospectively using age, Charlson comorbidity index ...
People also search for
